Why ImmunoGen Could See Another 60% of Potential Upside
ImmunoGen shares benefited after the company presented data for its latest assessment of mirvetuximab soravtansine at the Society of Gynecologic Oncology annual meeting.
Health and Healthcare
All Health and Healthcare Articles
Newest first · Page 141
4 Jefferies Biotech Stocks to Buy That Could Be Acquired Within 18 Months
While there is no guarantee that these four biotech companies are acquired, they are outstanding stocks to own in aggressive growth portfolios on their own.
How Analysts See AbbVie After the Big Disappointment
AbbVie shares took a big step back last week after the firm reported less than favorable results for its relapsed/refractory small cell lung cancer trial.
Pfizer’s Chantix Study Goes Up in Smoke
Pfizer shares slipped slightly on Friday after the pharma giant announced results from its Chantix/Champix smoking cessation study in adolescents.
Is the FDA Expecting More Problems for Progenics?
Progenics Pharmaceuticals shares took a big step back on Friday after the firm announced that it received an update from the FDA.
AbbVie Slides on Weak Midstage Results
AbbVie saw its shares pull back on Thursday after it reported less than favorable midstage results for its relapsed/refractory small cell lung cancer trial.
Prothena Climbs on Celgene Collaboration
This collaboration with Celgene looks like a chance for Prothena to really shine, especially considering that it has had a rough run of 2018 so far.
FDA Looks to Crack Down on Menthol Cigarettes and Maybe More
Smoking seems to be the next hot topic with the FDA, with the agency considering banning or restricting menthol and other flavors from tobacco products.
Arena Pharmaceuticals Wins Big in Midstage Trial
Arena Pharmaceuticals shares climbed early on Tuesday after the firm announced positive midstage results from its Phase 2 trial for etrasimod.
Cidara Therapeutics Sinks Despite Positive Midstage Results
Cidara Therapeutics shares took a big step back on Monday, despite the firm reporting positive topline results from its Phase 2 Strive clinical trial of its lead antifungal candidate.
Even More Biopharma Catalysts Coming Through the End of March
Here, 24/7 Wall St. has included a calendar of some of the biggest companies expecting clinical trial and FDA updates for the rest of March.
JPMorgan Has 3 Top Biotechnology Picks With Huge Upside Potential
These three top companies have solid catalyst potential and already have shown good clinical results on their leading assets.
Alexion Wins Big in Late-Stage Trial
Alexion Pharmaceuticals watched its shares make a solid gain on Thursday after the firm announced positive results from its late-stage trial of ALXN1210.
RBC Says 4 Health Care Stocks Are Potential 2018 Buyout Candidates
It happens every year, and 2018 won’t be any different. Larger companies looking to add to growth, beyond that of the organic or internal variety, scan the field for purchases and acquisitions that are…
Why Solid Biosciences Is Under Fire From the FDA
Solid Biosciences Inc. (NASDAQ: SLDB) watched its shares get crushed on Thursday after the company announced some complications with the U.S. Food and Drug Administration (FDA). Specifically, the FDA notified the firm that its…